Live-attenuated chikungunya virus vaccine.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38364787.
- Also identified by DOI 10.1016/j.cell.2024.01.033.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although Chikungunya fever does not a have a high fatality rate (<10%), it has a huge morbidity toll due to lingering chronic arthralgia. The recent FDA approval of Ixchiq, a vaccine designed to prevent infection caused by the chikungunya virus (CHIKV), provides hope that its use can prevent future CHIKV outbreaks. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Chikungunya Fever
- Chikungunya virus
- Viral Vaccines